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Cancer cells are differentially dependent on the splicing machinery compared to normal 
untransformed cells. The splicing machinery thus represents a potential therapeutic target in 
cancer.  To identify splicing factors important for prostate cancer cell (PCa) cell growth, we 
performed a parallel pooled shRNA screen on in vitro passaged cells and in vivo xenografted 
PCa tumor lines. Our screen revealed HNRNPM as a potential regulator of PCa cell growth. 
RNA- and eCLIP-sequencing data suggest that HNRNPM is bound to transcripts of key 
homeostatic genes and that loss of HNRNPM binding in a subset of these genes results in 
aberrant exon inclusion and exon back-splicing events in target transcripts. In both linear and 
circular mis-spliced transcripts, HNRNPM appears to preferentially bind to GU-rich elements 
in long flanking proximal introns. Mimicry of HNRNPM dependent linear splicing events using 
splice-switching antisense oligonucleotides (SSOs) was sufficient to inhibit cell growth in 
HNRNPM expressing cells. This suggests that prostate cancer cell dependence on HNRNPM 
is likely a result of mis-splicing of key homeostatic coding and non-coding genes. Taken 
together, our data reveal a role for HNRNPM in supporting prostate cancer cell fitness, and 
also as a potential therapeutic target in PCa.   
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In eukaryotic cells, many genes harbor intronic sequences that are removed during 
RNA splicing and transcript maturation (Venter et al., 2001). This process is regulated by the 
spliceosome, comprising of small non-coding RNAs (U1, U2, U4, U5 and U6), the core 
spliceosomal proteins (U2AF1, U2AF2, SF3B1 etc.) and other auxiliary factors (Wahl, Will, & 
Luhrmann, 2009). Under normal physiological conditions, proper regulation of splicing 
provides the cell an opportunity to control gene expression in the absence of genetic 
alterations. By expressing alternative isoforms of the same gene, the cell can regulate both 
the inclusion/exclusion of specific protein and/or RNA domains (Ellis et al., 2012; Yang et al., 
2016) or change transcript half-life (Lareau & Brenner, 2015; Naro et al., 2017; t Hoen et al., 
2011), thus impacting both transcript fate and function. 
The regulation of alternative splicing plays a central role in development (Baralle & 
Giudice, 2017) , cellular differentiation (Pimentel et al., 2016) as well as in the cellular 
response to external or internal stimuli (Hang et al., 2009; Haque, Ouda, Chen, Ozato, & Hogg, 
2018; Makino, Kanopka, Wilson, Tanaka, & Poellinger, 2002; Shalgi, Hurt, Lindquist, & Burge, 
2014). However, the same phenotypic plasticity offered by the splicing machinery can work 
against the cell and organism, and confer competitive advantages to cells under pathological 
conditions such as cancer. Indeed, alterations in the expression of specific isoforms of certain 
genes and of splicing factors themselves can promote cell proliferation (e.g. Androgen 
Receptor (AR); Liu et al. (2014)) , metastasis (e.g. CD44; (Todaro et al., 2014; Xu et al., 2014)) 
or avoid apoptosis (Dewaele et al., 2016; Schwerk & Schulze-Osthoff, 2005) in cancer. Some 
of these changes in isoform ratios may be direct results of mutations in the linear motifs that 
comprise the splice sites (Bartram et al., 2017; Jung et al., 2015; Puente et al., 2015) or in the 
splicing machinery itself (Graubert et al., 2011; Papaemmanuil et al., 2011; Wang et al., 2011; 
Yoshida et al., 2011).   
In addition to the differential splicing of specific genes, there is also increasing 
evidence that some molecular subtypes of cancer, which bear mutations in non-splicing 
related genes such as MYC, are highly dependent on a functional core spliceosome for 
survival (Hsu et al., 2015; Koh et al., 2015). This may be related to their high proliferation 
rates, which require them to heavily rely on the splicing machinery.  
Thus, there is evidence for a strong involvement of the RNA splicing in cancer. The 
splicing machinery and its associated factors may offer selective therapeutic vulnerabilities. 
However, the identify of critical targets, the context in which they function, their mechanisms 
of action, and the functional impact of the individual splicing factors in cancer remain unknown. 
To address this, we performed a parallel pooled in vivo and in vitro shRNA screens against 
core and auxiliary splicing factors in prostate cancer (PCa). Through this screen, we were able 
to uncover a novel role for the heterogeneous nuclear ribonucleoprotein M (HNRNPM). 
HNRNPM expression is higher in PCa than in normal prostate epithelial cells, and its loss 
affects PCa cell growth in vitro and in vivo. RNA-seq and eCLIP suggests that HNRNPM 
binding differentially impacts the splicing and/or expression of distinct classes of transcripts. 
Interestingly, we found that HNRNPM is limits circular RNA biogenesis within cells. Overall, 
our work offers mechanistic insight into the function of HNRNPM in prostate cancer and 





A targeted pooled shRNA screen identifies splicing-related dependencies in PCa.  
In order to identify major splicing factor dependencies in prostate cancer, we 
conducted parallel pooled in vitro and in vivo shRNA screens in the LNCAP prostate cancer 
cell line (Fig 1A). In such a screen, shRNAs targeting essential genes and oncogenes are 
generally depleted as the cell population increases, whereas shRNAs that target tumor 
suppressors and negative regulators of proliferation become enriched. The screens utilized a 
lentiviral library of 520 shRNAs targeting 102 core and auxiliary splicing factors, meaning 3 to 
5 shRNAs targeting each gene (Table S1). After puromycin selection, we harvested a portion 
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of the cells to be used as the control input pool (P1). The remaining cells were either passaged 
continuously in vitro for about 28-30 population doublings (about 1 month; ~9 passages), or 
xenografted into the flanks of SCID mice and allowed to form tumors over time. In vitro 
passaged cells were harvested at every other passage for DNA isolation (P3, P5, P7, P9). In 
vivo tumors were harvested for DNA isolation when they attained a size of 400mm3 or more. 
shRNA hairpin enrichment levels in individual samples were quantified via high throughput 
sequencing. Input lentiviral and plasmid pools were also sequenced as controls.  
For analysis, individual hairpin abundances were normalized to the control input pool 
(P1). Multidimensional scaling (MDS) analysis of the data showed P1 clustering with the 
plasmid and lentiviral controls, confirming that hairpin abundances in our input pool of cells 
were representative of our initial library (Fig 1B). Tumor samples were clustered away from 
P1 samples, indicating a shift in overall hairpin distribution in these samples. Notably, for the 
in vitro passaged samples, samples derived from the later passages clustered closer to tumor 
samples, while samples derived from the earlier passages clustered more closely to the input 
group of samples (Fig 1B), possibly underscoring similarities in the functional 
enrichment/depletion patterns during cell proliferation. Consistently, we identified five well-
defined clusters of hairpin enrichment/depletion, with similar patterns of enrichment/depletion 
in both in vitro passaged and in vivo tumor samples (Fig S1A).  
To identify top hits in our screen, we subjected our dataset to a rotational gene set 
analysis (Wu et al., 2010) (Fig 1C; Tables S2 and S3). This analysis takes into account the 
overall enrichment levels of individual hairpins targeting the same gene and compares them 
against each other. Because the majority of hairpins in our screen appeared to be depleted 
over time both in vitro and in vivo (Fig S1A), this suggested that many of the hits we found 
were likely to be essential genes within cells. To distinguish between essential genes from 
genes that had a potential oncogenic function, we further performed a short-term (96 hours), 
independent siRNA screen (Fig 1D) for our top hits (two-sided p ≤ 0.01, FDR≤0.05) on normal, 
untransformed prostate epithelial cells (PrEC). We rationalized that an acute reduction in 
expression of essential genes would likely be deleterious in these cells. On the other hand, 
reduced expression of genes that were more likely to be important for oncogenic growth 
should minimally inhibit PrEC cell growth. Indeed, short term, reduced expression of several 
genes, such as SF3A1, SRSF1, SRSF2, which are essential genes that form part of the core 
spliceosomal machinery, was rapidly deleterious in the PrEC cells (Fig 1D). On the other hand, 
reduced expression of HNRNPM and HNRNPF mildly affected proliferation in the PrEC cell 
line, suggesting a long-term oncogenic as opposed to an essential role for these genes in PCa 
(Fig 1D). To further narrow down the hits from our screen, we reanalyzed publicly available 
gene expression data sets for prostate cancer (TGCA). This analysis correlated the increased 
expression of HNRNPM with poorer disease-free survival over time, while this was not the 
case for HNRNPF (Fig S1B). In addition, western blot analysis suggested that expression of 
HNRNPM is increased in PCa cells, but not in normal PrEC cells (Fig 1E). Taken together, 
HNRNPM is a valid target for further analysis. 
 
HNRNPM is required for PCa cell proliferation in vitro and in vivo 
We first validated our screen results using shRNAs (TRCN0000001244; 2B7, 
TRCN0000001246; 2B9) present in the screen (Fig 2A and 2B). These hairpins were efficient 
in reducing HNRNPM protein and RNA levels (Fig 2A and 2B). In line with the screen results, 
reduced HNRNPM mRNA and protein levels in LNCAP cells resulted in reduced cell 
proliferation (Fig 2C). Moreover, we showt that HNRNPM depletion imparirs colony formation 
(Fig 2D) and anchorage-independent cell growth (Fig 2E), underscoring a broad role for 
HNRNPM in preserving cell fitness. HNRNPM dependency appeared similar in the PC3 
prostate cancer cell line (Fig S2A-E), which bears different driver mutations (PTEN null, TP53 
null, Androgen independent) from LNCAP (PTEN null, TP53 wildtype, Androgen 
dependent)(van Bokhoven et al., 2003). This suggests that the impact of HNRNPM in PCa is 
not dependent on specific tumor genotypes or hormone-dependency. Finally, the ability of 
LNCAP cells to form tumors when xenografted in mice was impaired in HNRNPM-depleted as 
compared to control cells (Fig 2F, Fig S2F). The reduction in cell proliferation and growth 
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correlated with potency of HNRNPM protein depletion by individual hairpins, supporting an 
on-target effect (Fig 2 and Fig S2). These results suggest that HNRNPM is important for 
maintaining PCa cell growth both in vitro and in vivo.  
 
HNRNPM is bound to GU-rich elements within long genes 
To further understand the molecular role of HNRNPM in PCa, we next performed 
eCLIP (Van Nostrand et al., 2016) on LNCAP cells to identify direct RNA targets of HNRNPM. 
eCLIP analysis (Fig S3A-C; eCLIP controls) revealed 57984 high confidence (p-value <= 0.05, 
Fold enrichment >= 1.5) HNRNPM bound sites in LNCAP cells (Fig 3A, S3B and S3C), 
spanning 6510 gene bodies. These sites were primarily located in intronic regions of 
expressed genes, with very few binding sites found at either intergenic or exonic loci (Fig 3B). 
Genes bound by HNRNPM were surprisingly much longer on average (p<2.2e-16; Fig 3C), 
with median lengths of 3880bp, compared to the median lengths of 845bp in all Ensembl 
transcripts. HNRNPM-bound sites tended to be guanidine and uridine (GU) rich (Fig 3D and 
3E), and motif analyses of these sites revealed sequences consisting of single or double G 
residues interspersed with one to two U residues (Fig 3E).  
 
Loss of HNRNPM results in minor changes in total mRNA levels 
HNRNPM binding to pre-mRNA could potentially alter either transcript abundance or 
splicing. To better understand the impact of reduced HNRNPM binding in PCa cells, we further 
performed RNA sequencing on LNCAP PCa cells that were transduced either with the 
scrambled shRNA or HNRNPM-specific shRNAs (2B7 and 2B9) (Fig S4A, Fig 4A, Table S4). 
When compared to scrambled shRNA control treated cells, the overall transcript abundance 
shifts in both populations of HNRNPM shRNA-treated cells were positively correlated with 
each other (Fig 4A), suggesting that majority of the effects observed on the transcriptome 
were specific to a reduction in HNRNPM levels. Expression analyses revealed that: (1) only 
0.58% (38 of 6510 mapped and bound genes) of HNRNPM-bound RNAs varied significantly 
(p<0.05, FDR <0.05, Fold Change >= 2 in both shRNA conditions) in expression levels during 
HNRNPM depletion in either knockdown condition (Table S5), and that (2) a minority (19.04%; 
38 of 189 differentially and significantly expressed) of transcripts that were significantly altered 
in expression during HNRNPM knockdown were also bound by HNRNPM (Fig 4A, Table S5). 
These data suggested that the majority of transcript abundance changes occurring in these 
cells were not likely to be a direct consequence of HNRNPM depletion.  
 
Loss of HNRNPM results in increased exon inclusion 
Alternative splicing of transcripts can give rise to events such as changes to alternative 
3’ or 5’ splice site usage, cassette exon inclusion or exclusion or intron retention. To determine 
if some of these events were altered in HNRNPM depleted cells, we also performed splicing 
analyzes of our RNA sequencing dataset. These analyses revealed that the majority of 
significant splicing events affected by HNRNPM loss (p<0.05, FDR<0.05, dPSI>0.2) were the 
increased inclusion of cassette exons (Fig 4B). We observed few significant changes in 
alternative 5’ or 3’ splice site usage, in intron retention or in mutually exclusive exon usage in 
either shRNA conditions (Fig 4B).  
As skipped exon (SE) events were the dominant alteration in HNRNPM depletion, we 
focused on this group of events for further analyses. We found a core group of 135 SE events 
that were present and significantly altered in both shRNA conditions. 110 (81.5%) of the core 
135 identified events were found in genes that were bound by HNRNPM (Fig 4C, Table S6). 
Of these 110 events, 96 (87.3%) were events where the cassette exon displayed increased 
inclusion (lower left quadrant, Fig. 4C). We were able to independently validate several of 
the events (Fig 4D) via RT-PCR. Taken together, these data suggested that the majority of 
splicing changes occurring in HNRNPM-depleted cells were highly likely to be a direct 
consequence of reduced HNRNPM binding and that HNRNPM depletion tends to result in 
increased exon inclusion.  
To better understand the specificity of HNRNPM towards its target introns, we 
examined the surrounding genomic and structural features of exons that were differentially 
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included upon HNRNPM depletion. HNRNPM-silenced exons in linear transcripts were 
flanked by introns that were significantly longer (-1 flank median: 3327bp; +1 flank median: 
2498bp; Fig. 4E) than other introns in the same transcripts (median:1826bp), or across the 
genome (median: 1434bp). HNRNPM binding sites were also preferentially found in these 
introns compared to other introns of the same transcript (Fig. 4F). Target exons appeared to 
bear weaker 5’ and 3’ splice sites compared to original flanking splice sites (Fig 4G). 
Overall, we can conclude that HNRNPM is enriched in the long proximal introns of mis-spliced 
exons. 
 
Loss of HNRNPM results in increased circular RNA formation 
Aside from regulating alternative splicing events in linear mRNA, the splicing 
machinery is also known to catalyze the formation of exon-back splicing events in pre-mRNA 
to generate circular RNAs (CircRNAs). While the biological functions for most circRNAs 
remain unclear, their expression is highly regulated and specific to different tissue and cell 
types (Hansen et al., 2013; Memczak et al., 2013).  
To determine if HNRNPM regulates circRNA biogenesis, we analyzed our RNA-
sequencing dataset for backsplicing events. We identified a total of 1357 circularized 
transcripts in LNCAP cells amongst which 332 circRNAs that were significantly changed in 
expression. More circRNAs (230/340) were upregulated in HNRNPM deficient cells, 
suggesting that HNRNPM typically inhibits the formation of these RNAs (Fig 5A and 5B, Table 
S7). The vast majority of these circular RNAs were multi-exonic (312/340) (Fig 5C). We were 
able to validate several of these events in RNaseR treated RNA with RT-PCR using divergent 
PCR primers (Fig 5D). Similar to our observations for the linear events, we also observed that 
the majority (88.55%; 294/340) of transcripts that had changes in back-splicing were bound 
by HNRNPM (Fig 5A), suggesting that the differences in back-splicing frequency observed in 
HNRNPM-depleted cells is likely to be a direct consequence of reduced HNRNPM binding.  
Similar to linear transcripts, introns flanking (-1 flank median: 17.5 kb; +1 flank median: 
17.2 kb) HNRNPM-silenced circularizing exons were significantly longer than other introns 
(median:2320bp) in the same transcripts, or across the genome (Fig 5E). HNRNPM binding 
sites were also enriched in the proximal 5’ and 3’ introns flanking differentially circularized 
exons. Fewer HNRNPM binding sites were found in distal introns or introns within the 
circularized transcripts (Fig 5F). However, HNRNPM dependent back-spliced exons bore 
stronger 5’ and 3’ splice sites than that of the original flanking proximal exons (Fig 5G). 
Finally, we tried to understand if HNRNPM dependent circRNAs would contribute to 
prostate cancer progression. Circular RNAs have been reported to regulate gene expression 
through microRNA (miRNA) response elements as miRNA sponge, through proteins encoded 
in their sequences. Circular RNAs regulated by HNRNPM had few miRNA binding sites, 
suggesting that they were not likely to perform as miRNA sponges because most of them 
contained only 1-2 common miRNA response elements (MREs). The majority of HNRNPM 
dependent circular RNAs (231/294) were however predicted to have coding potential (Fig 5H, 
right panels).  
To then better understand the physiological relevance of these circRNAs, we took 
advantage of a recently published dataset (S. Chen et al., 2019) that analyzed circRNA 
expression in a cohort of 144 PCa patients. 248 of the 320 HNRNPM-regulated circRNAs were 
found expressed in patients. Expression of these circRNAs was also correlated with HNRNPM 
expression. Indeed, patients that had expressed higher levels of these circRNAs had 
significantly lower levels of HNRNPM (Fig 5I). Interestingly, low to mid expression of a cluster 
of HNRNPM-regulated circRNAs was significantly correlated with increased risk for patient 
biochemical relapse (BCR) (Fig 5J and S4B), and have a “tumor-suppressive” function. This 
was in-line with our observations that high HNRNPM levels, which are predicted to reduce the 
expression of these circRNAs, contributes to poorer prognosis in PCa. 
 
Structure-forming sequences are enriched in the flanking introns of mis-spliced events  
To determine if HNRNPM binding was indeed sufficient to inhibit exon inclusion, we 
adopted the use of a bi-chromatic splicing reporter that expresses either GFP or dsRed 
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fluorescent proteins, depending on the alternative splicing event that occurs (Fig 6A). 
HNRNPM binding sites of either the USP33 or APMAP transcripts were cloned into this 
reporter (Fig 6B, Table S8). As controls, we mutated predicted HNRNPM binding motifs (Fig 
3E) found at each site (Fig 6C). Flow cytometry analysis of 293T cells transfected with either 
reporter showed that introduction of a HNRNPM binding site to the reporter resulted in 
increased RFP expression as compared to the empty vector control (Fig 6D). This suggests 
that, as predicted, the presence of a HNRNPM binding site in the reporter was sufficient to 
cause exon skipping. Conversely, mutation of the HNRNPM binding sites in the reporter 
resulted in increased GFP expression (Fig 6D, right panels). Taken together, these data add 
support for our observations that the presence of HNRNPM is indeed required to suppress 
exon inclusion in cells. 
 
Overall, our observations suggest that HNRNPM preferentially binds to long introns in 
its target genes (Fig 4F and 5E), and that loss of binding in these introns results in 
accumulation of mis-splicing events. In long introns, RNA secondary and tertiary structures, 
stemming from competitive long and short range pairings between short inverted repeat (IR) 
sequences, has been shown to be partially required for appropriate splice site selection (Jeck 
et al., 2013; Rogic et al., 2008; Zhang et al., 2014) . These pairings can be intra- or inter- 
intron, and may function to shorten effective branchpoint distance or mask cryptic splice sites. 
Such IR pairs tend to be derived from repetitive elements (short-interspersed nuclear 
elements; SINEs, long-interspersed nuclear elements; LINEs). We therefore examined if there 
was differential association of HNRNPM with these elements in mis-spliced transcripts but not 
in unaffected transcripts. Approximately 43.7% of HNRNPM bound peaks across the 
transcriptome were associated with at least one class of repetitive element (LINE, SINE, 
repetitive DNA, or long terminal repeats (LTR)) (Fig S5A; All binding sites; bottom panel)). 
In contrast, 54.1% and 50.5% of HNRNPM binding sites found within the proximal flanking 
introns of mis-spliced exons in linear and circular transcripts intersected with such elements 
(Fig S5A; top left and middle panels). Consistent with previous observations, L1 LINE 
elements represented the major class of repeats that HNRNPM peaks were associated with 
(Fig S5B; Kelley, Hendrickson, Tenen, and Rinn (2014)).  
 Recent studies have also suggested that HNRNP interactions with RNA tertiary 
structures such as RNA G quadruplexes (GQ) can impact splicing outcomes (Huang, Zhang, 
Harvey, Hu, & Cheng, 2017). Given that HNRNPM preferentially binds to GU-rich sequences, 
we also investigated if sequences found within flanking introns of mis-spliced events have the 
potential to form GQ structures. In linear transcripts, we observed an increased incidence of 
potential GQ forming sequences per kb of intron length in the intron upstream of the mis-
splicing events (Fig S5C; left panel), compared to other introns in the same transcript. In 
contrast, potential GQ structures were enriched in both the upstream (-1) and downstream 
(+1) introns flanking mis-spliced circRNA events (Fig S5C; right panel). GQ, when 
complexed with hemin, has peroxidase activity that can be detected upon addition of 
substrate by a maximal absorbance at 420nm (Li et al., 2013). Using this assay, we were 
also able to confirm that several HNRNPM bound sequences had the capability to form tertiary 
GQ structures (Fig S5D). Examination of local secondary structure (+/- 1kb) by DMS-MaP 
sequencing around representative HNRNPM binding peaks in the flanking introns of five mis-
splicing events in GMPR2, PRKAB2, USP33, ZNF548, ZNF304 also revealed the presence 
of many local structures at and around HNRNPM binding sites (Fig S5E-G). Formation of 
these structures however did not appear to be HNRNPM-dependent (Fig S5G). 
 
Mimicking the inclusion of HNRNPM-silenced poison exons by splice switching 
antisense oligonucleotides inhibits cell growth 
Changes to alternative splicing can affect transcript fate and function(Ellis et al., 2012; 
Lareau & Brenner, 2015; Naro et al., 2017; t Hoen et al., 2011; Yang et al., 2016). This, in 
turn, leads to changes in both the cell’s transcriptome and proteome, manifesting as 
phenotypic transformations.  Because the main impact of HNRNPM depletion were changes 
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in alternative splicing, but not gene expression, we focused on the exon inclusion and 
circularization events that were changed upon HNRNPM knockdown. Gene ontology analysis 
of these genes suggested that most of these genes are involved in specific key cellular 
processes (Fig 7A), including histone lysine methylation and the regulation of microtubule 
polymerization.  
The majority of HNRNPM-dependent linear splicing events were predicted to result in 
nonsense mediated decay (NMD) or alternative reading frames in their target protein (Fig 7B), 
suggesting that the functions or protein levels of many of these targets were likely to be altered 
in HNRNPMlow cells. To determine if the mis-splicing of some of these genes contributed to 
the reduction in cell growth, we designed splice switching antisense oligonucleotides (SSOs) 
to induce three HNRNPM-specific exon retention events in HNRNPM-sufficient LNCAP cells. 
Transfection of SSOs targeting splicing events occurring in EED, PRKAB2, and ZNF548 
recapitulated splicing events occurring in HNRNPM deficient cells (Fig 7C), and led to the loss 
of cell viability in target cells. As a control, we used an SSO against HNRNPM that is predicted 
to result in NMD of the HNRNPM transcript. Our results suggest that the reduction in cell 
growth in HNRNPM deficient cells is likely a result of perturbing multiple genes across different 
pathways.  
 
EED isoform 2 is a novel splicing target of HNRNPM 
While HNRNPM loss resulted in NMD events, a significant portion of them also resulted 
in alternative proteins (Fig 7B). One such event occurred in the EED transcript, which our 
SSO data suggested was growth inhibitory. We were interested in understanding why this was 
so. Loss of HNRNPM expression resulted in increased inclusion of EED exon 10, resulting in 
a 25-amino acid added in-frame to the EED protein. To determine how this may affect EED 
function, we analyzed and modelled the structure of EED protein with or without the peptide 
extension. Wildtype EED contains seven copies of the WD-repeat motif, and folds into a 
seven-bladed beta-propeller structure. We found that addition of the peptide sequence into 
the structure results in disruption of hydrogen bonding within the beta sheet of WD repeat 5 
(Fig 7D, 7E and S6A). This is likely to disrupt the stability of the WD repeat, and affect EED 
function. In support of this, we find that induction of this specific isoform of EED in LNCAP 
cells is correlated with reduced H3K27me3 activity (Fig 7F). These results suggest that loss 
of EED function is likely to contribute to the reduced proliferation we observed upon HNRNPM. 
Indeed, analyses of the TCGA data sets suggest that patients with reduced EED expression 





Recent evidence suggests that cancer cells may be especially vulnerable to 
disruptions in their splicing machinery than normal, untransformed cells (Braun et al., 2017; 
Hsu et al., 2015; Koh et al., 2015). This is thought to be a consequence of increased 
proliferative rates and transcriptional outputs, resulting in “addiction” to a highly functioning 
spliceosome. Despite this, splice signatures amongst different cancers can vary (Sebestyen, 
Zawisza, & Eyras, 2015), suggesting that unique or sets of splicing factors may regulate 
different splicing programs across different cancer types. For instance, ESRP1 has been 
suggested to drive both oncogenic (Fagoonee et al., 2017) and tumor suppressive (Shapiro 
et al., 2011; Ueda et al., 2014) programs in the context of different cancers. Identification of 
key factors that underpin a cancer-type specific splicing program is, therefore, valuable in the 
development of downstream therapeutics. 
To this end, we have, through an unbiased and systematic screen of splicing factors, 
identified HNRNPM as a potential vulnerability in prostate cancer (Fig 1). HNRNPM depleted 
LNCAP prostate cancer cells fail to expand both in vitro and in vivo (Fig 2). Our data suggest 
that the arrest in cell proliferation in HNRNPM-depleted cells is likely a consequence of mis-
splicing, as opposed to an alteration of transcript abundance. Indeed, using antisense 
oligonucleotides to mimic several of these splicing events in cells that expressed HNRNPM 
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was sufficient to inhibit cell proliferation and growth (Fig 7C). In support of this, we showed 
that an exon inclusion event in the EED transcript results in destabilization of one of its WD-
repeats, and is likely to contribute to reduced PRC2 complex activity in PCa cells (Fig 7D-G). 
We have also showed that the majority of circRNAs regulated by HNRNPM are expressed in 
PCa patients, and that their expression levels are anti-correlated with that of HNRNPM (Fig 
5I). Reduced expression of these circRNAs resulted in poorer disease-free survivals in these 
patients (Fig 5J). Taken together, HNRNPM likely regulates PCa cell proliferation by 
suppressing exon inclusion and circularization of multiple transcripts across many key 
homeostatic pathways in cells.  
Interestingly, the phenotypic manifestation of HNRNPM loss in prostate cancer cells is 
different from what was previously described. Here we describe a role for HNRNPM in 
maintaining cell fitness but did not observe changes in cell identity programs in PCa cells. In 
breast cancer cells, where loss of HNRNPM inhibits epithelial-mesenchymal transition (EMT), 
but not cell growth(Xu et al., 2014). Together, these data are consistent with a context-
dependent function for HNRNPM in cancer, which might depend on its downstream targets. 
Interestingly, the herein identified downstream target EED controls cell proliferation and EMT 
in context-dependent manner(Serresi et al., 2016; Shi et al., 2013).  
 Splicing defects occurring during HNRNPM deficiency primarily involve increased exon 
inclusion and exon circularization, indicating that HNRNPM normally functions to suppress 
splice site usage in PCa. This is consistent with previous observations on splicing during 
HNRNPM loss in other cell types (Damianov et al., 2016; Huelga et al., 2012; Xu et al., 2014). 
Our data indicate that mis-spliced linear-splicing and circularization events occurring during 
HNRNPM deficiency are located in exons that are flanked by HNRNPM-bound introns. 
HNRNPM occupancy is much lower in other introns in the same transcripts, suggesting that 
its recruitment is important for ensuring appropriate splice site selection. 
  Members of the hnRNP family of proteins have been shown to be important in 
ensuring correct splice site selection in target genes. These proteins tend to interact with cis-
regulatory splicing silencer sequences in pre-mRNA, and several hnRNPs have also been 
identified as repressors of splicing (Matlin, Clark, & Smith, 2005).  hnRNP-mediated splicing 
repression has been attributed to several modes of action, including antagonizing core 
spliceosomal components and/or splicing enhancer proteins from binding to pre-mRNA 
(Mayeda, Helfman, & Krainer, 1993; Mayeda & Krainer, 1992; Zhu, Mayeda, & Krainer, 2001), 
as well as alteration of long-range secondary structure in pre-mRNA to inhibit/promote 
alternate splice site usage (Blanchette & Chabot, 1999; Martinez-Contreras et al., 2006; 
Solnick & Lee, 1987). These modes of action are not mutually exclusive, and some hnRNPs 
(e.g. hnRNPA1) have been shown to rely on both, depending their binding context (Blanchette 
& Chabot, 1999; Martinez-Contreras et al., 2006; Mayeda et al., 1993; Mayeda & Krainer, 
1992).  
 Our analyses suggest that HNRNPM specifically prevents mis-splicing in the context 
of long genes and is especially enriched in long introns across the genome.  Increased intron 
length has been shown to adversely affect correct splice site selection. For one, cryptic splice 
sites that compete with the original 5’ and 3’ splice sites are more likely to be found within a 
longer intron. Secondly, increased intron length extends the delay between RNA polymerase 
II-dependent synthesis of the 5’ and its associated 3’ splice sites, resulting in a higher 
probability of RNA secondary and/or tertiary interactions forming to bridge a 5’ss and an 
incorrect proximal cryptic 3’ss.  
 Formation of RNA secondary and tertiary structures has been shown to be partially 
required for correct splice site selection in long introns (Rogic et al., 2008; Zhang et al., 2014). 
In vertebrates, large introns bear relatively high densities of repetitive regions that are 
predicted to form both intra- and inter- intron complementary base pairings (Shepard, 
McCreary, & Fedorov, 2009). Such pairings may be long range ( >1.4 kb apart; Aktas et al. 
(2017)) and are typically formed between long or short interspersed repetitive elements (LINEs 
and SINEs). Competition between such pairs of complementary sequences has been shown 
to significantly alter splice site selection in both linear and circular transcripts (Zhang et al., 
2014). It may be that HNRNPM is required to regulate the formation or interactions between 
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these structures at such transcripts, in order to maintain correct splice site selection. In line 
with this, HNRNPM was previously shown to interact with several ATP-dependent RNA 
helicases (Brannan et al., 2016), pointing to a possible association with RNA 
secondary/tertiary structure. We also observe that HNRNPM is more enriched at repetitive 
elements in mis-spliced transcripts than other bound transcripts. Long flanking introns that 
flank mis-splicing events in HNRNPM deficiency also have a higher tendency to form G-
quadruplex structures. Interestingly, we do not observe local (<1kb flanking HNRNPM bound 
sites) changes in secondary structure immediately surrounding HNRNPM bound sites. It could 
be that HNRNPM is more important for mediating cross-intron interactions or required for 
regulating RNA tertiary structures.  
Finally, it has been previously reported that long, alternatively spliced genes, bearing 
elevated intron length to exon length ratios, are highly enriched in pathways associated with 
cancer and other multi-genic diseases (Sahakyan & Balasubramanian, 2016). Understanding 
how this class of genes is regulated may thus be critical for developing therapeutics against 
these diseases. Because of their lengths, expression of this class of genes can be rate-limiting 
for cell survival and/or function. Inhibition of transcription elongation by blocking 
topoisomerase activity is sufficient to impair their expression (King et al., 2013). In a similar 
vein, we have shown that expression of these genes may also be especially vulnerable to 
depletion of splicing factors such as HNRNPM.  One prediction that arises from this 
observation is that expression of these genes may be modulated through synergistic 
interactions between inhibitors targeting transcription elongation and splicing factors. Indeed, 
there is some evidence in the literature pointing towards this. Mutations in the splicing factors 
SRSF2 and U2AF1 have been shown to impair transcription pause-release and drive R loop 
formation (L. Chen et al., 2018), suggesting that these two pathways are intimately linked. 
Identification of other factors similar to HNRNPM that may similarly affect homeostasis of 
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MATERIALS AND METHODS 
Cell Culture and treatment 
LNCAP (ATCC) and PC3 (ATCC) cells were cultured and maintained in RPMI media 
supplemented with 10% fetal bovine serum (FBS; Lonza) 1mM sodium pyruvate (Gibco, 
11360070), non-essential amino acids (Gibco; 11140050) and 50U/ml Penicillin-Streptomycin 
(Gibco, 15140163). Primary prostate epithelial cells (PrEC; Lonza, CC-2555) were cultured in 
PrEGM Prostate Epithelial Cell Growth Medium (Lonza, CC-3165) supplemented with BPE, 
Hydrocortisone, hEGF, Epinephrine, Transferrin, Insulin, Retinoic Acid, Triiodothyronine and 
GA-1000 as per the manufacturer’s recommendation (Lonza, CC-4177). HEK293T (ATCC) 
cells were maintained in DMEM media supplemented with 10% FBS, 1mM sodium pyruvate, 
non-essential amino acids, and 50U/ml Penicillin-streptomycin. 
 
Lentivirus production and infection 
For single lentivirus generation, HEK293T cells were seeded to 50% confluency one day prior 
to transfection with the PLKO.1 vector of interest, packaging (d8.9) and envelope plasmids 
(VSVg) in the ratio of 5:5:1, using Lipofectamine 2000 reagent (Invitrogen). Fresh media was 
added to the transfected cells after an 18h incubation. Subsequently, cell culture supernatant 
containing lentiviral particles was collected at both 24h and 48h post media-change, filtered 
with a 0.22 μm filter, and concentrated by ultracentrifugation at 4°C, 23000 RPM for 2 hours. 
For pooled lentivirus generation, PLKO.1 vectors of interest were pooled prior to transfection 
in HEK293T cells with packaging and envelope plasmids. Ratios of vectors used were 
maintained as stated in the procedure used for single lentivirus production.  
 
shRNA pooled screen  
The screens were conducted as previously described (Gargiulo, Serresi, Cesaroni, Hulsman, 
& van Lohuizen, 2014), with modifications. 5E6 LNCAP cells were seeded one day prior to 
infection in 150mm dishes, and infected with lentivirus pools at a multiplicity of infection of 1, 
in the presence of 8ug/ml polybrene. After a 48hour infection, cells were selected in 1ug/ml 
puromycin for 4-5 days. Upon completion of selection, cells were trypsinized and counted. 
1.5E6 cells were harvested and saved as the input control for sequencing. The remaining cells 
were used either for in vitro passaging or in vivo tumorigenesis experiments. For the in vitro 
passaging experiments, 1.5E6 cells were plated in a 150mm dish and cells were harvested 
every 3-4 population doublings, with 1.5E6 cells harvested and plated at each passage. 
Harvested cell pellets were flash frozen and stored at -80C. For each injected tumor in the in 
vivo tumorigenesis experiments, 1.5E6 cells were re-suspended in 100ul of cell culture media 
mixed with Matrigel in a 1:1 ratio. Cells were then injected into the flanks of 6-8 week old, male 
CB17-SCID mice (In Vivos) and allowed to form tumors over time. Mice were monitored for 
tumor growth every 2-3 days. Tumors were harvested when they attained a size of 400mm3 
and above. Harvested tumors were minced, trypsinized and ran through a 40um mesh to form 
single cell suspensions. Cell pellets were then flash frozen and stored at -80C. Genomic DNA 
from either the in vitro passaged or the in vivo tumor cell pellets was then harvested with the 
QIAGEN DNeasy kit in accordance to the manufacturer’s protocol. For lentivirus input libraries, 
RNA was isolated from ~3.5E6 infectious units of lentivirus using a combination of Trizol 
reagent (Invitrogen) and the Ambion Purelink RNA isolation kit. RNA was converted into cDNA 
using the Invitrogen Maxima cDNA synthesis reagent. shRNAs were amplified from genomic 
DNA or cDNA using primers spanning the common flanks of the shRNA expression cassette. 
These primers included adaptors for Illumina Hiseq sequencing. After PCR amplification, the 
constituent hairpins in each sample were identified through high-throughput sequencing, and 
the fold change in hairpin representation was determined by comparing the normalized reads 
of each sample to the relevant input (P1), plasmid and viral samples.  
 
Mice 
Mice were housed in compliance with the Institutional Animal Care and Use Committee 
(IACUC) guidelines. All procedures involving the use of mice were approved by the local 
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Institutional Animal Care and Use Committee (IACUC) and were in agreement with ASTAR 
ACUC standards. 
 
Short term siRNA screen 
1E4 PrEC cells per well in a 384 well plate were reverse transfected with siRNA using 
Lipofectamine RNAimax reagent (Invitrogen), to a final concentration of 25nM. siRNAs against 
PLK1 were used as a positive control, whereas control non-targeting siRNAs were used as 
negative controls. 96 hours post transfection, total cell yields were measured using the 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS), as per the 
manufacturer’s instructions. Absorbance readings (490nm) were taken at 2hours post 
incubation with the MTS solution. The relative impact of knockdown on cell growth was then 
determined by comparing absorbance readings from each sample well to that of the PLK1 or 
control non-targeting siRNA treated wells.  
 
RNA extraction and RT-PCR 
For RNA was isolated using the Purelink RNA Mini Kit (Thermo Fisher Scientific; 
12183018A)in conjunction with Trizol Reagent (Invitrogen; 15596018) following the 
manufacturer’s protocol. Following reverse transcription to cDNA with the Maxima First Strand 
cDNA synthesis kit (Thermo Fisher Scientific; K1641), 30ng of cDNA was used for each RT-
PCR reaction.  
 
Circular RNA validation 
RNA was purified as described above. After RNA isolation, 1ug of RNA was incubated with 
5U of RNaseR (Epicentre) for 45 min at 37C in a 14ul reaction volume to digest all linear RNA. 
After digestion, RnaseR treated RNA was reverse transcribed to cDNA using the Maxima 
cDNA synthesis kit, as per the manufacturer’s recommendation. Semi quantitative RT PCR 
was then performed on the cDNA using divergent primers to determine levels of circRNA 
across samples. CircRNA exon-exon joints were further confirmed by excising PCR amplified 
bands in the gel and performing sanger sequencing. 
 
Western blot analyses 
Cells were lysed in RIPA buffer (150mM sodium chloride, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 50mM Tris pH 8.0) for 30min on ice, before being subjected to 
sonication (10sec, Setting 4, Microson XL2000). 10-30ug of protein lysates were ran per lane 
in 10% SDS-PAGE gels for 1h 15min at 125V. Proteins were transferred onto 0.22um 
nitrocellulose membranes by wet transfer (Tris-Glycine buffer, 20% Methanol) at 30mA for 1-
2hours on ice. Membranes were blocked in 3% milk, before being incubated in the indicated 
antibodies overnight. Primary antibody bound membranes were then washed for 5 min three 
times in PBS+0.1% Tween-20, before being probed with HRP conjugated secondary 
antibodies for 45 min at room temperature. After three washes in PBS+0.1% Tween-20, 
membranes were probed with ECL, and imaged using film.  
 
eCLIP 
eCLIP experiments were performed as described in Van Nostrand et al. (2016), but with the 
following modifications: ~2.5E7 LNCAP cells were grown on 150mm dishes were UV 
crosslinked (150mJ), using the UV Stratalinker 2400. Cell pellets were flash frozen in liquid 
nitrogen and stored at -80C for > 1 day to facilitate lysis. Lysis was performed in 1ml ice cold 
iCLIP lysis buffer (50mM Tris-HCL pH7.5, 100mM NaCl, 1% Igepal CA630, 0.1% SDS, 0.5% 
Sodium deoxycholate and 1.1% Murine Rnase Inhibitor (M0214L, NEB). Cells were allowed 
to lyse for 15 min on ice, before a short sonication (3 min; 30 sec on / 30 sec off; low setting) 
in the Diagenode Bioruptor. Sonicated cell lysates were then treated with 40U of RnaseI 
(Ambion) and 4U of Turbo Dnase (Ambion) for 5 min at 37C.  RNase activity was inhibited 
with the addition of 1% SuperaseIn reagent, before being clarified with a 15000g centrifugation 
for 15 min at 4C. Clarified lysates were then subjected to an overnight IP at 4C, using 10ug of 
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HNRNPM antibody bound to Protein G dynabeads. 10% input samples were set aside prior 
to the addition of antibody-bead complexes.  
After the overnight IP, immunoprecipitated Protein-RNA complexes were treated with FastAP 
and PNK treated in the presence of SuperaseIn Rnase Inhibitors. This was followed by the 
ligation of a 3’RNA linker. The protein-RNA complexes were ran on a 1.5mm 4-12% NuPage 
Bis-Tris gel at 150V for 75min before being transferred on a 0.22um nitrocellulose membrane 
(30mA, 2hours). After the transfer, membranes were washed once in PBS. The regions 
corresponding to approximately 10KDa below and 75KDa above HNRNPM bound complexes 
were then excised. The region that was excised in this step was further confirmed to contain 
HNRNPM by running a separate western blot using aliquots of the same lysates. Excised 
membrane pieces were subjected to proteinase K digestion and RNA isolation in acid 
phenol/chloroform. The Zymo RNA Clean and Concentrator kit was used to purify the RNA 
containing aqueous layer from the phenol-chloroform extraction.  
After purification, extracted RNA was reverse transcribed, and a 5’ linker was ligated in an 
overnight DNA ligase reaction. Linker ligated cDNA was then subjected to clean up, and 
amplified using PCR. The final library was purified using 1.8X Ampure XP beads. Adapter 
dimers were removed using a second Ampure XP bead selection step with 1.4X bead to eluate 
ratio. Library sizing was checked using the DNA high sensitivity Bioanalyzer chip, and libraries 




For proliferation assays, 8E3 LNCAP cells per well in a 96 well plate were reverse transfected 
with SSOs using the Lipofectamine RNAimax reagent to a final concentration of 100nM. 
Control, non-targeting SSOs were used as controls. Total cell yields were measured using the 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) at 48 hours post 
transfection, as per the manufacturer’s instructions.  
Since the majority of the splicing events we were interested in were deleterious to cells, as 
compared to the non-targeting controls, reduced concentrations of SSOs were used in order 
to lower overall transfection efficiency and recover sufficient RNA and protein for downstream 
analyses. 3E5 LNCAP cells were reverse transfected with SSOs to a final concentration of 
25nM, and harvested at 48hours post transfection. For protein assays, cell pellets were lysed 
in RIPA buffer containing protease inhibitors, before being briefly sonicated. After sonication, 
lysates were centrifuged (14000rpm, 4’C, 10 min) to remove cellular debris, and the resulting 
supernatant was quantified and used in western blot assays. RNA isolation was performed as 
described above.   
 
Bioinformatics analysis 
RNA sequencing reads were mapped to the hg19 genome using STAR v2.4.2a (Dobin et al., 
2013). Differential expression analysis was done using the Cufflinks suite v2.2.1 (Trapnell et 
al., 2012), and alternative splicing analysis was done using rMATS 3.0.9 (Shen et al., 2014), 
both using the Ensembl release 72 human annotation. Downstream splicing predictions was 
carried out using SPLINTER (Low, 2017 ). 
e-CLIP-seq analysis was performed according to the protocol outlined in Van Nostrand et al. 
(2016)with several modifications outlined here.  Briefly, pseudo paired-end reads were first 
created from single-end reads using bbmap in the BBTools suite (https://jgi.doe.gov/data-and-
tools/bbtools/).  The first 6bp of reads were also removed in the adapter-trimming step to 
improve alignment quality. Subsequent downstream analyses post-protocol were carried out 
using in-house R scripts. 
 
CircRNA expression and HNRNPM expression in PCa Patients 
Patient clinical attributes and circRNA expression levels were obtained from Ref (S. Chen et 
al., 2019). A circRNA was considered as highly expressed in a patient if it was expressed at 
levels that were at the 75th percentile of that of the cohort. To calculate HNRNPM expression 
levels in different groups of patients, the number of highly expressed circular RNAs were first 
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counted per patient. Patients were stratified by those that had most numbers of high expressed 
circRNAs (>75th percentile of cohort; Group=High), least (≤25th percentile of cohort; 
Group=Low) or Mid-range (25th-75th percentile of cohort; Group=Mid).  HNRNPM levels for 
each group was then plotted.  
 
CircRNA expression and BCR Survival in PCa Patients 
Patient clinical attributes and circRNA expression levels were obtained from Ref (S. Chen et 
al., 2019). For each circRNA, [atients were stratified by those that had high expression 
circRNAs (>75th percentile of cohort; Group=High), low expression (≤25th percentile of cohort; 
Group=Low) or Mid-expression (25th-75th percentile of cohort; Group=Mid).  Biochemical 
Relapse survival curves and hazard ratios were then calculated using the ‘Survival’ package 
in R. 
Fragment Length Analysis PCR (FLAPCR) 
30ng of cDNA was amplified using 2X DreamTaq Mastermix (ThermoFisher, EP1701) and 
primers specific to the splicing target of interest. Forward primers were FAM-labelled. PCR 
products were amplified using the following program: 94°C for 5 minutes, then 30 3-steps 
cycles (94°C for 30”, 56°C for 45” and 72°C for 45”) and subsequent 8 3-steps cycles (94°C 
for 30”, 52°C for 45” and 72°C for 45”) with a final cycle at 72°C for 3 minutes. 1ul of the PCR 
product was added to 9.1 ul of HiDi + Liz markers premix (GeneScan 500/1200 LIZ dye Size 
Standard, ThermoFisher #4322682/4379950, optimized to give 1K RFU peak height) to each 
sample. The mix was denatured at 96°C for 3 minutes, cooled at 4°C for 3 mins and run in the 
ThermoFisher 3730XL DNA Analyzer. GeneMapper 5 (ThermoFisher) software was used to 
analyze the peaks.  
 
Splicing Reporter Assays 
Bichromatic fluorescent splicing reporter plasmid (RG6) were previously described in Ref 
(Orengo, Bundman, & Cooper, 2006) and obtained from Addgene (Plasmid #80167). Briefly, 
RG6 was digested with EcoRI and XhoI. Inserts corresponding to HNRNPM binding regions 
for APMAP1 (chr20:24945080-24945163; Hg19) and USP33 (chr1:78224956-78225074; 
Hg19) were cloned in. Sequences are shown in Table Sx. Where necessary, HNRNPM 
binding sites were mutated using QuikChange XLII Mutagenesis Kit (Stratagene). For flow 
cytometry assays, 2.5ug of each plasmid was transfected into 5E5 HEK293T cells. 2 days 
post transfection, cells were trypsinized and strained through a 40uM filter. Flow cytometry 
experiments were performed on the BD LSRII. Only singlet and live cells (as determined by 
DAPI dye exclusion) were analyzed. Analysis was performed with FCS Express 6.0. 
In vivo DMS probing.  
LNCaP cells were trypsinized for 1 minute at 37°C, trypsin was neutralized by addition of fresh 
serum-containing medium, and harvested by centrifugation at 4°C for 5 minutes. After aspiring 
medium, cells were washed once in PBS, and resuspended in DMS Probing Buffer [10 mM 
HEPES-KOH pH 7.9; 140 mM NaCl; 3 mM KCl]. DMS was pre-diluted 1:6 in ethanol, then 
added to the cell suspension to a final concentration of 100 mM. Cells were incubated at 25°C 
with moderate shaking for 2 minutes. Reaction was quenched by placing cells in ice, and 
immediately adding DTT to a final concentration of 0.7 M. Cells were briefly collected by 
centrifugation for 1 minute at 9,600g (4°C). Supernatant was aspired, and cells were washed 
once with a solution of 0.7 M DTT in PBS. 
 
Isolation of nascent RNA.  
The pellet from a 75%-confluence 100mm plate was resuspended in 150 μl of Cytoplasm 
Buffer [10mM Tris HCl pH 7; 150 mM NaCl] by pipetting using a cut P1000-tip. 50 μl of 
Cytoplasm Lysis Buffer [0.6% NP-40; 10mM Tris HCl pH 7; 150 mM NaCl] were slowly added 
dropwise, after which sample was incubated on ice for 2 minutes. The lysate was then layered 
on top of a 500 μl cushion of Sucrose Buffer [10mM Tris HCl pH 7; 150mM NaCl; 25% 
Sucrose]. Sample was then centrifuged at 16,000g for 10 minutes (4°C). The supernatant 
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(representing the cytosolic fraction) was discarded, and the nuclei were washed in 800 μl of 
Nuclei Wash Buffer [0.1% Triton X-100; 1mM EDTA in 1X PBS], then collected by 
centrifugation at 1,150g for 1 minute (4°C). After removing the supernatant, nuclei were 
resuspended in 200 μl of Glycerol Buffer [20mM Tris HCl pH 8; 75mM NaCl; 0.5mM EDTA; 
50% Glycerol; 10mM DTT] and resuspended by pipetting, then transfered to a clean tube. 200 
μl of Nuclei Lysis Buffer [1% NP-40; 20mM HEPES pH 7.5; 300mM NaCl; 2M UREA; 0.2mM 
EDTA; 10mM DTT] were then added dropwise, while gently vortexing the sample. The sample 
was then incubated on ice for 20 minutes, then centrifuged at 18,500g for 10 minutes (4°C). 
The supernatant (representing the nucleoplasm) was discarded, and the chromatin fraction 
was washed once with Nuclei Lysis Buffer, without letting the pellet detach from the bottom of 
the tube. After discarding the supernatant, 1 mL of ice-cold TRIzol was added directly to the 
chromatin fraction, and the sample was incubated at 56°C for 5 minutes to solubilize 
chromatin. RNA extraction was performed by adding 200 μl of Chloroform, vigorously mixing 
for 15 seconds, then centrifuging at 12,500g for 15 minutes (4°C). After centrifugation, the 
upper aqueous layer was transferred to a new tube, and mixed with 3 volumes of ethanol by 
vigorously vortexing for 15 seconds. The sample was then loaded on a Zymo RNA Clean & 
Concentrator-5 column, and purified following manufacturer instructions. 
 
RNA G-quadruplex Hemin Assays 
Hemin assays for G quadruplex formation were conducted as previously described (Zheng et 
al., 2015). Briefly, RNA oligos corresponding to wildtype or mutated sequences of HNRNPM 
binding sites found in the introns of EED, USP33 and PRKAB2 transcripts were ordered from 
IDT DNA. The sequences of these oligos are found in Table S9. RNA oligos were first 
suspended to 10uM in folding buffer (20 mM Tris pH 7.6, 100 mM KCl, 1 mM EDTA). They 
were then heated to 98oC in a water bath and allowed to come to room temperature through 
passive cooling. Folded RNAs were incubated with 12uM of Hemin (Sigma H-5533, in DMSO) 
in 1X Buffer 2 (New England Biolabs) at 37oC for 1 hr. Substrate solution (2 mM ABTS, Sigma 
A9941; 2 mM hydrogen peroxide, Sigma H1009; 25 mM HEPES pH7.4, 0.2 M NaCl, 10 mM 
KCl, 0.05% Triton X-100, 1% DMSO) was then added to each mixture. After 15min, 
absorbance of each sample was measured from 400nm to 500nm using a SpectraMax 
Plus384 Microplate Reader. Samples containing RNA G-quadruplexes display the 
characteristic absorbance peak at 420nm. 
 
Targeted DMS-MaPseq. 
DMS-MaPseq was performed with minor changes to the original protocol (Zubradt et al., 
2017). Oligonucleotides were designed to amplify regions not exceeding a length of 600 nt. 
Reverse transcription was carried out in a final volume of 20 μl. 1 μg of nascent RNA was 
initially mixed with 2 μl of 10 mM dNTPs and 1 μl of 10 μM gene-specific primers, then 
denatured at 70°C for 5 minutes, after which the sample was allowed to slowly cool to room 
temperature by incubation for 5 minutes on the bench. Reaction was started by addition of 4 
μl 5X RT Buffer [250 mM Tris-HCl, pH 8.3; 375 mM KCl; 15 mM MgCl2], 1 μl 0.1 M DTT, 20 U 
SUPERase• In™ RNase Inhibitor, and 200 U TGIRT™-III Enzyme. Sample was incubated at 
50°C for 5 minutes, followed by 2 hours at 57°C. Reaction was stopped by addition of 1 μl 
NaOH 5M. Sample was then incubated at 95°C for 3 minutes to detach the reverse 
transcriptase and degrade the RNA. cDNA cleanup was performed using Zymo RNA Clean & 
Concentrator-5 columns, following manufacturer instructions. PCR amplification of target 
intronic regions was performed using 10% of the purified cDNA for each primers pair and 
AccuPrime™ Taq DNA Polymerase (high fidelity), following manufacturer instructions. PCR 
products were resolved on a 2% Agarose gel, the bands of the expected size were gel-purified 
and pooled in equimolar amounts. Sample were then sheared by 20 cycles of sonication using 
a Diagenode Bioruptor® sonicator [30'' ON; 30'' OFF; Power: high]. Libraries were prepared 
using the NEBNext® Ultra™ II DNA Library Prep Kit for Illumina®, following manufacturer 
instructions. 
 
DMS-MaPseq data analysis.  
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Data analysis was performed using the RNA Framework v2.5 (http://www.rnaframework.com) 
(Incarnato, Neri, Anselmi, & Oliviero, 2016) All tools were used with default parameters, except 
for the rf-map tool that was called with the parameter -mp "--very-sensitive-local". The 
percentage of mutations per base was calculated by normalizing the number of mutations on 
that base by the frequency of that base in the reference (e.g. the number of mutations 
occurring on A residues, divided by the total number of As present in the analyzed introns). 
 
Accession Numbers 
RNA Sequencing and eCLIP data have been deposited in the NCBI GEO repository, 
accession number GSE113786. Data for circRNA in prostate cancer patients was obtained 
from Ref (S. Chen et al., 2019), NCBI GEO repository accession number: GSE113120. 
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Figure 1: A pooled shRNA screen identifies HNRNPM as a regulator of PCa cell growth. 
(A) Schematic of overall experimental design. (B) MDS plot of individual samples (in vitro 
passaged cells and tumors) collected in the screen, in relation to each other. (C) (Right) Venn 
Diagram showing overlap of significant hits for in vitro and in vivo screens (Left) Ranked 
dotplots showing –log10(p-values) of in vivo and in vitro screen hits. Red circles represent 
significant hits. Tumor-specific hits are indicated (D) Barplots showing overall PrEC cell 
proliferation upon a 96 hour, siRNA mediated knockdown of the indicated splicing factors, as 
measured through a colorimetric MTS assay. siRNAs that inhibit cell proliferation relative to 
the scrambled siRNA control are indicated in black, while siRNAs that do not alter cell 
proliferation are indicated in green. Each assay was performed in 2 biological replicates, with 
two technical duplicates per replicate. Error bars represent s.d, *: p<0.05 compared to 
scrambled. (E) Western blot of HNRNPM protein levels in PrEC, LNCAP and PC3 cells. 
Tubulin is shown as a loading control.  
  
Figure 2: HNRNPM inhibits PCa cell growth in vitro and in vivo. HNRNPM RNA (A) and 
protein levels (B) upon expression of scrambled or HNRNPM specific shRNAs in LNCAP cells. 
(C) Cell proliferation assays of LNCAP cells expressing with either scrambled or HNRNPM 
specific shRNAs (2B7 and 2B9). (D) colony formation assays and (E) Anchorage independent 
growth (soft agar assays) of shRNA treated LNCAP cells (F) Size of xenografted, scrambled 
or HNRNPM specific shRNA expressing LNCAP cells at 60 days post injection in 6-8 week 
old SCID-CB17 mice (n=10-11 per condition). 
 
Figure 3: HNRNPM binds GU rich elements within long introns. (A) Normalized read 
density of HNRNPM eCLIP at the HNRNPM and PRAM1 genes. Input (yellow) and 
immunoprecipitation (red) tracks are shown. High confidence (p<0.05, Fold enrichment >2) 
peaks are shown in the lowest track. (B) Distribution of HNRNPM bound peaks across different 
genomic features (C) Distribution of gene lengths in all genes (blue) or HNRNPM bound genes 
(red) (D) Histogram plot of nucleotide frequencies within called, high confidence HNRNPM 
bound peaks. (E) Motif analysis of HNRNPM bound peaks. Shown are the top three (from top 
to bottom; p=1e-726, p=1e-625 and p=1e-597) motifs found within intragenic HNRNPM bound 
sites. 
 
Figure 4. HNRNPM depletion results in increased exon inclusion (A) Scatterplot of all 
significantly changed (p<0.05, FDR<0.05) genes (grey point) in HNRNPM shRNA treated 
cells, and their HNRNPM binding status. HNRNPM bound genes are highlighted in orange. 
Red boxes denote a 2 fold change cut off. The total numbers of differentially expressed genes 
(p<0.05, FDR<0.05, fold change >=2) are indicated in black, and the numbers of genes that 
are differentially expressed and bound by HNRNPM are indicated in red. (B) Plots showing all 
alternative splicing events occurring in 2B9 shRNA treated cells. All unique captured events 
are plotted in grey, while significantly changing events are shown in red. Change in percent 
spliced in (DPSI; HNRNPM shRNA (2B9) versus Scrambled shRNA) for the captured events 
is shown on the x axis. A similar plot for HNRNPM shRNA 2 (2B7) is shown in Figure S4b. RI: 
Retained Intron; A3SS: Alternative 3’ splice site usage; A5SS: Alternative 5’ splice site usage; 
MXE: Mutually exclusive exons; SE: Skipped Exon (C) Scatter plot of splicing events that are 
significantly changed (p<0.05, FDR<0.05, |DPSI| > 0.2)  in both HNRNPM shRNA (2B7 and 
2B9) conditions. Shown in red are events that occur in transcripts that are bound by HNRNPM. 
(D) RT-PCR validation of differentially spliced events that occur in HNRNPM depleted cells. 
(E) Distribution of unique intron lengths in the upstream (-1) or downstream (+1) introns 
flanking linear mis-splicing events compared to that of other introns in the same transcript or 
across the transcriptome. P-values were determined by the Wilcoxon test. (F) Distribution of 
the numbers of HNRNPM binding sites across the indicated introns in transcripts with linear 
mis-splicing events. (G) 5’ (right) and 3’ (left) splice site strength as compared to original, 
flanking splice sites in HNRNPM-dependent linear transcripts. 
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Figure 4. HNRNPM depletion results in increased circular RNA formation. (A) Scatterplot 
of CircRNA events that are significantly (p<0.05, FDR<0.05) changed in sh2B7 or sh2B9 
treated cells compared to scrambled shRNA treated cells. All individual captured events are 
plotted in grey, genes highlighted in orange are bound by HNRNPM. (B) Distribution of 
upregulated and downregulated circular RNAs in HNRNPM deficient cells. (D) Distribution of 
multi-exonic or single exon circular RNAs regulated by HNRNPM. (D) Semi quantitative RT-
PCR validation of circular RNA events occurring in sh2B7 or 2h2B9 treated cells. (E) 
Distribution of unique intron lengths in the upstream (-1) or downstream (+1) introns flanking 
circular mis-splicing events compared to that of other introns in the same transcript or across 
the transcriptome. P-values were determined by the Wilcoxon test. (F) Distribution of the 
numbers of HNRNPM binding sites across the indicated introns in transcripts with circular mis-
splicing events. (G) 5’ (right) and 3’ (left) splice site strength as compared to original, flanking 
splice sites in HNRNPM-dependent circular transcripts. (H) Distribution of HNRNPM-
dependent circular RNAs that encode ORFs or have miRNA-response elements. (I) HNRNPM 
expression levels in patients that express high, mid and low levels of target circRNAs (J) 
Heatmap showing the log2(Hazard Ratios) of patients expressing low or mid levels of the 
indicated circRNAs, when compared to patients expressing high levels of the same circRNA. 
 
Figure 5: Genomic and structural features of HNRNPM-dependent silenced exons. (A) 
Schematic showing outcomes of minigene splicing assay (B) Plots showing HNRNPM bound 
regions of the USP33 and APMAP gene that were cloned and inserted into the minigene 
construct (C) Flow cytometry plots showing differential splicing patterns of cells that were 
transfected with the indicated constructs. Left: No plasmid control; Right: Unmodified vector 
control. Y-axis shows increasing levels in exon inclusion and x-axis shows increasing levels 
of exon skipping. (D) Flow cytometry plots showing differential splicing patterns of cells that 
were transfected with the indicated constructs. Left: Vectors with wildtype HNRNPM binding 
site, Right: Vectors with mutated HNRNPM binding site. Y-axis shows increasing levels in 
exon inclusion and x-axis shows increasing levels of exon skipping.  
 
Figure 6: Mimicking HNRNPM-dependent linear splicing events in cells inhibits cell 
growth. (A) Gene-ontology analysis of transcripts that are either changed in expression or 
mis-spliced upon HNRNPM knockdown.  (B; leftmost Panels) Schematic showing cell growth 
and exon inclusion outcomes in SSO treated cells as compared to scrambled SSO treated 
cells. (B, right panels) Distribution of predicted outcomes of HNRNPM-dependent linear 
splicing events occurring in coding domains of affected genes. (C) Scatter plots of overall cell 
growth yields (y-axis) in relation to overall exon inclusion levels (x-axis) upon treatment of the 
specified SSOs. Relative exon inclusion levels were measured and calculated based on target 
peak areas determined by FLA-PCR. Values are shown relative to cells treated with scrambled 
SSOs. Labels: SCR: Scrambled SSO; HNRNPM: HNRNPM-NMD inducing SSO; Numbered 
labels: Indices of gene-specific SSOs that induce inclusion of target HNRNPMlow-dependent 
exons. A representative of two experiments is shown. (D) WD40 domain 5 of EED when the 
HNRNPM-regulated exon 10 is included. Structure of the HNRNPM regulated WD40 domain 
in wildtype EED (Grey), superimposed on the predicted structure of the HNRNPM-dependent 
EED isoform (blue) The new peptide generated by the splicing event is depicted in orange. 
(E) Close up view of hydrogen bonding interactions that stabilize the WD40 beta sheet in either 
wild-type or the new EED isoform. (F) Western blot of H3K27me3 (EED target) upon HNRNPM 
loss or EED event (G) Disease free survival curves of PCa patients when expression of EED 
is low (blue) or high (red)  
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SUPPLEMENTARY FIGURE LEGENDS 
 
Figure S1 (Related to Figure 1): Verification of top hits in the pooled shRNA screen. 
(A) Heatmap showing overall hairpin enrichment over time in in vitro passaged LNCAP cells 
(left), in vivo LNCAP xenografts (center) as well as input PLKO.1 plasmid and lentiviral pools 
(right). Colors are shown in relation to the first passage of cells collected after completion of 
puromycin selection (P1), where blue indicates depletion and red indicates enrichment of the 
individual hairpin over time. (B) Disease-free survival curves of Prostate cancer patients that 
express high (>75th percentile) or low (≤25th percentile) of HNRNPM or HNRNPF. Data were 
plotted using GEPIA (Tang et al., 2017) and based on publically available TCGA datasets. 
 
Figure S2 (Related to Figure 2): Impact of HNRNPM deficiency in an independent PCa 
cell line  
HNRNPM RNA (A) and protein levels (B) upon expression of scrambled or HNRNPM 
specific shRNAs in PC3 cells. (C) Cell proliferation assays of PC3 cells expressing with 
either scrambled or HNRNPM specific shRNAs (2B7 and 2B9). (D) colony formation assays 
and (E) anchorage independent growth (soft agar assays)of shRNA treated PC3 cells (F) 
Western blotting and RNA analysis of cells used for xenograft experiments (top panel). 
qPCR analysis of RNA isolated from tumors harvested from xenografted mice at 60 days 
post injection (bottom panel). Each dot indicates one tumor. 
 
Figure S3 (related to Figure 3). eCLIP analysis of HNRNPM binding sites. (A, left) 
Immunoprecipitation-western blot validation of anti-HNRNPM antibody pull down efficiency 
in UV-crosslinked LNCAP lysates. (A, center) Scan of membrane showing regions excised 
for eCLIP library preparation. (A, right) High-sensitivity DNA Bioanalyzer traces of eCLIP 
libraries used for sequencing. (B and C) Read density of HNRNPM eCLIP at a HNRNPM 
bound locus, TJP1 (C) and a non-bound locus, GAPDH (B). Bars indicate high confidence 
(p<0.05, fold enrichment > 2) called eCLIP peaks.   
 
Figure S4 (related to Figure 4 and 5). Controls related to Figure 4 and 5. (A) RNA 
sequencing read density at the HNRNPM locus in scrambled and HNRNPM (2B7 and 2B9) 
shRNA treated cells. RNA sequencing tracks at the GAPDH housekeeping gene is shown as 
a control. (B) Biochemical relapse survival curves of prostate cancer patients expressing 
high (>75th percentile), low (≤25th percentile) or mid (25th-75th percentile) levels of the 
indicated circular RNAs.  
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Figure S5: Structural Characterization of HNRNPM bound introns (A) Distribution of 
unique HNRNPM peaks found in the immediate flanking upstream and downstream introns of 
mis-spliced linear (top left panel) or circular (top right panel) mis-splicing events that share a 
>10% overlap with one or multiple classes of 4 types of repetitive elements (LINEs, SINEs, 
DNA and LTR). The overlap of these elements with HNRNPM peaks found across the 
transcriptome is indicated in the bottom panel. (B) Types of LINE elements associated with 
HNRNPM binding sites at mis-spliced linear (top left panel) and circular (top right panel) 
transcripts, compared to that in regions bound by HNRNPM (bottom panel) across all 
transcripts (C) Distribution of G-quadruplex forming regions in the upstream (-1 or -2) or 
downstream (+1 or +2) introns relative to mis-spliced linear (left) or circular (right) events. 
Counts are normalized to the length of the intron.  (D) Colorimetric, hemin based assay for 
RNA G-quadruplex folding. RNA oligos of HNRNPM binding sites of the USP33, EED and 
PRKAB2 genes were folded in the presence of potassium, and incubated with hemin. The 
presence of RNA G-quadruplexes in conjunction with hemin results in a peroxidase activity, 
which can be detected as an increase in absorbance at 420nm. As a negative control, the 
same test oligos with mutated GQ sites was used (dotted lines) (E) HNRNPM protein levels 
in cells used for targeted DMS-MaPseq. (F) Base mutation frequencies in Scrambled shRNA 
or HNRNPM (2B9) shRNA treated LNCAP cells. (G) Overall correlation of the structure 
probing data for Scrambled shRNA and HNRNPM shRNA (2B9) treated cells. Representative 
HNRNPM bound sites in the introns flanking mis-splicing events for PRKAB2, USP33, 
ZNF548, ZNF304, GMPR2, GAPDH were used for this analysis. 
 
Figure S6: HNRNPM regulates a multigenic splicing program to maintain cell 
proliferation (A) Structure of the HNRNPM regulated WD40 domain in wildtype EED protein 
(Grey), superimposed on the predicted structure of the HNRNPM-dependent EED isoform 
(blue) that contains the 25 aa long peptide coded by the exon regulated by HNRNPM. The 
new peptide generated by the splicing event is depicted in orange. WD domains in EED are 
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SUPPLEMENTARY TABLE LEGENDS 
Table S1: Table of shRNAs and sequences used for pooled screens (Related to Figure 1 and 
S1) 
Table S2: Rotational Gene Set Analysis (ROAST) results: Tumor versus Input (P1) (Related 
to Figure 1C) 
Table S3: Rotational Gene Set Analysis (ROAST) results: In vitro (Related to Figure 1C) 
Table S4: Gene Expression Changes in all HNRNPM bound genes (Related to Figure 4A) 
Table S5: Binding Status of all significantly differentially expressed genes in HNRNPM 
knockdown (Related to Figure 4A) 
Table S6: Binding Status of Significantly Changed Skipped Exon Events (Related to Figure 
4B and 4C) 
Table S7: Binding Status of Significantly Changed Circular RNAs (Related to Figure 5A) 
Table S8: Sequences used for Bichromatic Splicing Reporter (Related to Figure 6) 
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